Last reviewed · How we verify

NCT04705935

Amniochorionic Membrane Cells in the Maternal Blood as a Biomarker for Preterm Birth

Completed Last updated 18 December 2024
What this trial tests

trial in Preterm Birth in 83 participants. Completed in 28 June 2024.

Timeline
15 August 2022
Primary endpoint
28 June 2024
28 June 2024

Quick facts

Lead sponsorUniversity of Aarhus
StatusCompleted
Study typeOBSERVATIONAL
Enrollment83
Start date15 August 2022
Primary completion28 June 2024
Estimated completion28 June 2024
Sites1 location across Denmark

Conditions studied

Sponsor

University of Aarhus

Who can join

18 and older, female only, with Preterm Birth or Preterm Premature Rupture of Membrane. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Globally, preterm birth (15 mill. per year) is the leading cause of under-5 child mortality (1 mill. per year) and morbidity. Important pathways include preterm labor contractions, Preterm Prelabor Rupture of the Fetal Membranes (PPROM), and iatrogenic delivery. At labor, the fetal amniochorionic membrane undergoes a cellular senescence and shed fetal amniochorionic membrane cells (ACM cells) to the maternal circulation. In collaboration with the private firm ARCEDI Biotech and The University of Texas Medical Branch at Galveston, Aarhus University has identified specific antibodies, which can be used to isolate ACM cells from maternal blood. Thus, the aim of this study is 1) to characterize ACM cells by histological and immunological techniques, and 2) in a cohort assess their performance as biomarkers of amniochorionic membrane dysfunction, including early detection of threatening preterm birth. In perspective, the findings are expected to improve the diagnostics and treatment of preterm birth.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Preterm Birth

Currently open trials in the same condition.

Other University of Aarhus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04705935.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing